Bronchiectasis Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Bronchiectasis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Bronchiectasis Research. Learn more about our innovative pipeline today! @ Bronchiectasis Pipeline Outlook- https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Bronchiectasis Pipeline Report
• In November 2024:- Sanofi- A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis
• In November 2024:- Boehringer Ingelheim- This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term.
• In November 2024:- Verona Pharma plc- The primary objective of this study is to assess the effect of ensifentrine vs placebo in addition to standard of care on pulmonary exacerbations, symptoms and quality of life in participants with NCFBE. The study is designed as a pulmonary exacerbation event-driven study where participants will be treated for ≥ 24 weeks and until 120 subjects have experienced at least 1 protocol-defined pulmonary exacerbation. Participants will be randomized to receive either ensifentrine suspension or placebo via standard jet nebulizer during the treatment period and neither participants nor study staff will know which a participant is receiving.
• DelveInsight's Bronchiectasis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment.
• The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A., and others.
• Promising Bronchiectasis Therapies such as CHF6333, Itepekimab (SAR440340), Aztreonam lysine, Nebulized Ensifentrine Suspension; 3 mg, and others.

Stay informed about the cutting-edge advancements in Bronchiectasis treatments. Download for updates and be a part of the revolution in care @ Bronchiectasis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchiectasis Emerging Drugs Profile

• Benralizumab: AstraZeneca
Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. Currently, being evaluated in Phase III stage of clinical trial evaluation to treat Non-cystic Fibrosis Bronchiectasis.

• S1226: SolAeroMed
S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways.The rescue treatment works on both physiological and biophysical principles offering a unique approach to relieving airway obstruction. CO2 is a potent, but short acting bronchial smooth muscle relaxant. Perflubron is a non-toxic (biocompatible) medical perfluorocarbon with mucolytic and surfactant properties that acts synergistically with CO2 to provide a much greater and more prolonged broncho-dilatory effect. The drug product is hypothesized to open constricted airways through at least three distinct mechanisms. Firstly, through the relaxant effect of CO2 (alone and dissolved into perflubron) on constricted airway smooth muscle; secondly, by lowering surface tension in the inflamed airways; and finally by possibly facilitating penetration and lubrication of mucus plugs, thus enhancing mucociliary clearance. Furthermore it works by an entirely different mechanism to the ß-adrenergic agonists and thus complements, rather than replaces, existing treatments.

• Brensocatib: Insmed
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs

Learn more about Bronchiectasis Drugs opportunities in our groundbreaking Bronchiectasis Research and development projects @ Bronchiectasis Unmet Needs- https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchiectasis Companies
AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A., and others.

Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Bronchiectasis Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Discover the latest advancements in Bronchiectasis treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Bronchiectasis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bronchiectasis Pipeline Report
• Coverage- Global
• Bronchiectasis Companies- AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A., and others.
• Bronchiectasis Therapies- CHF6333, Itepekimab (SAR440340), Aztreonam lysine, Nebulized Ensifentrine Suspension; 3 mg, and others.
• Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Bronchiectasis Pipeline on our website @ Bronchiectasis Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Bronchiectasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Bronchiectasis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. S1226: SolAeroMed
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CSL787: CSL Behring
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. AP-PA02: Armata Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Bronchiectasis Key Companies
21. Bronchiectasis Key Products
22. Bronchiectasis- Unmet Needs
23. Bronchiectasis- Market Drivers and Barriers
24. Bronchiectasis- Future Perspectives and Conclusion
25. Bronchiectasis Analyst Views
26. Bronchiectasis Key Companies
27. Appendix

List of Highly Demanded Research Reports in 2024

cxcr inhibitors market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
fertility monitoring devices market: https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
ornithine transcarbamylase deficiency market: https://www.delveinsight.com/report-store/ornithine-transcarbamylase-deficiency-otc-deficiency-market
orthopedic power devices market: https://www.delveinsight.com/report-store/orthopedic-power-devices-market
otitis media market: https://www.delveinsight.com/report-store/otitis-media-market
persistent depressive disorder market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
smoking cessation market: https://www.delveinsight.com/report-store/smoking-cessation-market
surgical sealant market: https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
urothelial carcinoma market: https://www.delveinsight.com/report-store/urothelial-carcinoma-market
vascular grafts market: https://www.delveinsight.com/report-store/vascular-grafts-market
vital sign monitors devices market: https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
aplastic anemia market: https://www.delveinsight.com/report-store/aplastic-anemia-market
cart pipeline: https://www.delveinsight.com/report-store/car-t-pipeline-insight
celiac disease market: https://www.delveinsight.com/report-store/celiac-disease-cd-market
coronary stents market: https://www.delveinsight.com/report-store/coronary-stents-market-market
diabetic gastroparesis market: https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size
elastomeric pump market: https://www.delveinsight.com/report-store/elastomeric-pump-market
friedreich's ataxia market: https://www.delveinsight.com/report-store/friedreichs-ataxia-market
hay fever conjunctivitis market: https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
hip replacement devices market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
joint reconstruction devices market: https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
periodontal disease market: https://www.delveinsight.com/report-store/periodontal-disease-market
psoriasis vulgaris market: https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
ranibizumab biosimilars market: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
short bowel syndrome drug market: https://www.delveinsight.com/report-store/short-bowel-syndrome-market
short bowel syndrome market: https://www.delveinsight.com/report-store/short-bowel-syndrome-market
thrombectomy devices market: https://www.delveinsight.com/report-store/thrombectomy-devices-market
type 1 diabetes market: https://www.delveinsight.com/report-store/type-1-diabetes-market
adhd market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
attention deficit hyperactivity disorder market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
avascular necrosis market: https://www.delveinsight.com/report-store/avascular-necrosis-market
biopsy devices market: https://www.delveinsight.com/report-store/biopsy-devices-market
embolotherapy market: https://www.delveinsight.com/report-store/embolotherapy-market
hydrocephalus treatment market: https://www.delveinsight.com/report-store/hydrocephalus-treatment-market
liquid biospy for cancer diagnostics market: https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
skin grafting devices market: https://www.delveinsight.com/report-store/skin-grafting-devices-market
testicular neoplasm market: https://www.delveinsight.com/report-store/testicular-neoplasm-market
uk healthcare report: https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
vascular access devices market: https://www.delveinsight.com/report-store/vascular-access-device-market
brucellosis market: https://www.delveinsight.com/report-store/brucellosis-market
catheter stabilization devices market: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
dyspepsia market: https://www.delveinsight.com/report-store/functional-dyspepsia-market-share
heart pump devices market: https://www.delveinsight.com/report-store/heart-pump-device-market
phototherapies for psoriasis market: https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
radial artery compression device market: https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
sarcopenia market: https://www.delveinsight.com/report-store/sarcopenia-market
shingles market: https://www.delveinsight.com/report-store/shingles-market
surgical site infections market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
venous ulcer market: https://www.delveinsight.com/report-store/venous-leg-ulcer-market
viscosupplementation devices market: https://www.delveinsight.com/report-store/viscosupplementation-devices-market
artificial disc market: https://www.delveinsight.com/report-store/artificial-disc-market
healthcare consulting solutions: https://www.delveinsight.com/consulting
meningococcal meningitis market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
moderate to severe plaque psoriasis market: https://www.delveinsight.com/blog/us-psoriasis-treatment
pertussis market: https://www.delveinsight.com/report-store/pertussis-market
spinal trauma devices market: https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
surgical energy instruments market: https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
temporomandibular disorders market: https://www.delveinsight.com/report-store/temporomandibular-disorders-market
transcatheter heart valve replacement devices market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
urinary catheters market: https://www.delveinsight.com/report-store/urinary-catheters-market
attention deficit hyperactivity disorder adhd market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
coronary angioplasty market: https://www.delveinsight.com/report-store/coronary-stents-market-market
nonalcoholic steatohepatitis market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
orthopedic splints device market: https://www.delveinsight.com/report-store/orthopedic-splints-market
perennial allergic rhinitis market: https://www.delveinsight.com/report-store/perennial-allergic-rhinitis-market
pipeline assessment services: https://www.delveinsight.com/consulting/pipeline-assessment-services
schistosomiasis market: https://www.delveinsight.com/report-store/schistosomiasis-market
venous thromboembolism market: https://www.delveinsight.com/report-store/venous-thromboembolism-market
bacterial meningitis market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
nk cell therapy market: https://www.delveinsight.com/report-store/nk-cell-therapy-market
overactive bladder syndrome market: https://www.delveinsight.com/report-store/overactive-bladder-market
peripheral nerve injuries market: https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market
tendonitis market: https://www.delveinsight.com/report-store/tendonitis-market
endoscopic ultrasound market: https://www.delveinsight.com/report-store/endoscopic-ultrasound-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.